Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Macitentan 75 mg Test Formulations
NCT05392530Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- May 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of macitentan in pulmonary arterial hypertension (PAH) (6 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Maximum Observed Plasma Analyte Concentration, Area Under the Plasma Analyte Concentration-time Curve from Time Zero to Time of the Last Quantifiable Concentration and 1 more. Started May 2022; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05392530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05392530.